Literature DB >> 9637507

Molecular mechanisms of the induction of IL-12 and its inhibition by IL-10.

M Aste-Amezaga1, X Ma, A Sartori, G Trinchieri.   

Abstract

Exogenously added IL-10 rapidly inhibited Staphylococcus aureus- or LPS-induced cytokine mRNA expression in human PBMCs and monocytes, with a maximal effect observed when IL-10 was added from 20 h before until 1 h after the addition of the inducers. Nuclear run-on assays revealed that the inhibition of IL-12 p40, IL-12 p35, and TNF-alpha was at the gene transcriptional level and that the addition of IL-10 to S. aureus- or LPS-treated PBMCs did not affect mRNA stability. The inhibitory activity of IL-10 was abrogated by cycloheximide (CHX), suggesting the involvement of a newly synthesized protein(s). The addition of CHX at 2 h before S. aureus or LPS also inhibited the accumulation of IL-12 p40 mRNA, but did not inhibit IL-12 p35 and TNF-alpha mRNA. This finding suggests that p40 transcription is regulated through a de novo synthesized protein factor(s), whereas the addition of CHX at 2 h after S. aureus activation caused superinduction of the IL-12 p40, IL-12 p35, and TNF-alpha genes. These results indicate that in human monocytes, the mechanism(s) of IL-10 suppression of both IL-12 p40 and IL-12 p35 genes is primarily seen at the transcriptional level, and that the induction of the IL-12 p40 and p35 genes have different requirements for de novo protein synthesis.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9637507

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  98 in total

1.  Interleukin 10 treatment for rheumatoid arthritis.

Authors:  E W St Clair
Journal:  Ann Rheum Dis       Date:  1999-11       Impact factor: 19.103

2.  Inhibition of interleukin-12 production by auranofin, an anti-rheumatic gold compound, deviates CD4(+) T cells from the Th1 to the Th2 pathway.

Authors:  T S Kim; B Y Kang; M H Lee; Y K Choe; S Y Hwang
Journal:  Br J Pharmacol       Date:  2001-10       Impact factor: 8.739

3.  Characterisation, expression and promoter analysis of an interleukin 10 homologue in the puffer fish, Fugu rubripes.

Authors:  Jun Zou; Melody S Clark; Chris J Secombes
Journal:  Immunogenetics       Date:  2003-07-04       Impact factor: 2.846

4.  Interleukin-12: an update on its immunological activities, signaling and regulation of gene expression.

Authors:  Jianguo Liu; Shanjin Cao; Sunjung Kim; Elaine Y Chung; Yoichiro Homma; Xiuqin Guan; Violeta Jimenez; Xiaojing Ma
Journal:  Curr Immunol Rev       Date:  2005-06

5.  The protooncogene c-Maf is an essential transcription factor for IL-10 gene expression in macrophages.

Authors:  Shanjin Cao; Jianguo Liu; Lihua Song; Xiaojing Ma
Journal:  J Immunol       Date:  2005-03-15       Impact factor: 5.422

6.  Bordetella pertussis-infected human monocyte-derived dendritic cells undergo maturation and induce Th1 polarization and interleukin-23 expression.

Authors:  Giorgio Fedele; Paola Stefanelli; Fabiana Spensieri; Cecilia Fazio; Paola Mastrantonio; Clara M Ausiello
Journal:  Infect Immun       Date:  2005-03       Impact factor: 3.441

7.  The primary mechanism of the IL-10-regulated antiinflammatory response is to selectively inhibit transcription.

Authors:  Peter J Murray
Journal:  Proc Natl Acad Sci U S A       Date:  2005-06-03       Impact factor: 11.205

8.  Effects of strains of Lactococcus lactis on the production of nitric oxide and cytokines in murine macrophages.

Authors:  Chise Suzuki; Ayako Aoki-Yoshida; Hiromi Kimoto-Nira; Miho Kobayashi; Keisuke Sasaki; Koko Mizumachi
Journal:  Inflammation       Date:  2014-10       Impact factor: 4.092

Review 9.  The power of combinatorial immunology: IL-12 and IL-12-related dimeric cytokines in infectious diseases.

Authors:  Christoph Hölscher
Journal:  Med Microbiol Immunol       Date:  2003-06-27       Impact factor: 3.402

10.  PEG-rIL-10 treatment decreases FoxP3(+) Tregs despite upregulation of intratumoral IDO.

Authors:  Ivan H Chan; Victoria Wu; Melissa Bilardello; Brett Jorgenson; Harminder Bal; Scott McCauley; Peter Van Vlasselaer; John B Mumm
Journal:  Oncoimmunology       Date:  2016-06-27       Impact factor: 8.110

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.